Biomay announces positive Phase IIb study of BM32 grass pollen vaccine

Vienna-based allergy immunotherapy specialist Biomay has successfully completed a Phase IIb study of its grass pollen allergy vaccine BM32.

The study was designed to show sustained alleviation of allergy symptoms over two consecutive grass pollen seasons. The rhinoconjunctivitis symptom score during the peak pollen season in the second treatment was reduced by 25% compared to placebo. The treatment significantly improved patient wellbeing, as measured by two independent methods. The clinical effects observed were supported by a sustained induction of allergen-specific IgG antibodies, which block the interaction of allergens with IgE on effector cells. Established allergy vaccines derived from grass pollen extracts can lead to a boost in disease-causing IgE production, whereas BM32 did not.

The treatment was safe and well-tolerated, with most side-effects in the mild-to-moderate range.